safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
Published 2 years ago • 381 plays • Length 3:43Download video MP4
Download video MP3
Similar videos
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
3:21
safety management of car-t cell therapy in dlbcl
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
2:05
the cost-effectiveness of car t-cell therapy
-
3:05
car-t therapy in r/r dlbcl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:03
the impact of salvage and bridging therapy on car t-cell therapy outcomes in b-all: an itt analysis
-
1:35
key mechanisms of resistance to car t-cell therapy
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
0:59
the safety and efficacy of etavopivat in scd
-
1:01
engineering molecular on- and off-switches for controlling car t-cells
-
1:02
the use of car-t cell products in a real-world setting
-
1:45
a phase i/ii trial of glofitamab monotherapy in r/r mcl
-
1:32
car t-cell therapy: the importance of ltfu
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
8:27
anti cd7 car t-cell therapy in t-all